Rigvir is a company that engages in the production and development of oncolytic virotherapy cancer medicine. Its product RIGVIR is a virus-based immunomodulator with an anti-tumoral response for the treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma for prevention of relapse and metastases after radical surgery.